- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00820456
Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI
Angle Interleaved Projection Reconstruction With K-Space Weighted Image Reconstruction for Dynamic Contrast MRI of Cancer Therapy Response
The objectives for this study include:
- Testing a unique way of imaging people with colorectal cancer and other cancers that has spread to the liver using magnetic resonance imaging (MRI);
- Seeing if the MRI process can be used across multiple imaging platforms;
- Determining whether the results of the imaging can be reproduced;
- Reviewing how MRI results relate to cancer response to combination therapy and to clinical endpoints.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State University Hershey Medical Center
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, United States, 19017
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Arm A: Inclusion Criteria:
- Participants must be >18 years old;
- Participants must have an ECOG performance status of 0-1;
- Participants must not be pregnant or breastfeeding;
- Participants must have prior histological documentation of adenocarcinoma of the colon or rectum;
- Participants must be commencing chemotherapy with FOLFOX plus bevacizumab;
- Participants must not have had prior exposure to bevacizumab. Prior systemic chemotherapy with other agents is allowed. The last dose of systemic chemotherapy must have been > 3 months prior to study entry;
- Participants with prior radiotherapy or other prior local therapy to the liver (radioablation therapy, chemoembolic therapy) are acceptable. They must be at least 4 weeks past the last administration of such therapy;
- Participants must be at least 4 weeks past any major surgery, including surgery to the liver;
- Participants with prior malignancies other than colon cancer are allowed, provided they have been treated with curative intent, and have no evidence of recurrence of that malignancy;
- Participants must have a life expectancy of greater than 3 months;
- Participants must have the ability to understand and the willingness to sign a written informed consent form.
Arm B: Inclusion Criteria
- Participants must be >18 years old;
- Participants must have an ECOG performance status of 0-1;
- Participants must not be pregnant or breastfeeding;
- Participants must have prior histological documentation of any types of cancer with metastasis to the liver (see Imaging Criteria below);
- Participants must be projected to be within a stable treatment condition prior to and between scans (see section 4.3 for definition of stable treatment condition);
- Participants must be at least 4 weeks past any major surgery, including surgery to the liver;
- Participants must have a life expectancy of greater than 3 months;
- Participants must have the ability to understand and the willingness to sign a written informed consent form.
Imaging Criteria:
- Participants must have at least one hepatic lesion greater than or equal to 3 cm in maximal diameter on cross sectional imaging study (CT or MRI) performed within 4 weeks prior to study enrollment;
Participants must have at least one qualifying liver lesion (i.e. one greater than or equal to 3 cm) that has been confirmed metastatic adenocarcinoma of the colon or rectum based on one of the following criteria:
- Histologic (FNA or core biopsy) proof of malignancy compatible with metastasis from a colorectal carcinoma; OR
Demonstration of imaging features of tumor metastasis to the liver, including at least one of the following:
- evidence of heterogeneous enhancement or central tumor necrosis by CT or MRI;
- previously demonstrated interval enlargement of the lesion by >25% in the longest diameter;
- PET image demonstrating metabolic activity characteristic of malignancy (FDG uptake greater than that of background liver).
- For participants who have undergone local hepatic surgical, radiation, ablative, or embolic therapy, the date of qualifying imaging study(ies) or qualifying biopsy must be at least 30 days after the last instance of such local therapy. Furthermore, cross-sectional imaging performed at least 30 days after such local therapy must demonstrate an area of residual viable tumor (as judged by enhancing tissue following contrast administration) with longest diameter ≥ 3cm in at least one cross-sectional axis.
Arms A and B (Unless Otherwise Indicated): Exclusion Criteria:
Patients with contraindication to MRI, including:
- Contraindicated metallic device, including pacemaker, non-MRI compatible aneurysm clip, other non-MRI compatible mechanical and/or electrical device, or metallic fragments;
- Patients with severe claustrophobia (patients with milder forms of claustrophobia that can be successfully allayed with oral anxiolytic therapy are allowed);
Patients with contraindication to gadolinium, including:
a) Hypersensitivity to gadolinium-containing MR contrast agents;
- Severe impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73 m2 and/or on dialysis;
- Patients with severely compromised pulmonary, cardiovascular, or mental status. Patients must not have severe congestive heart failure (defined as New York Heart Association Class II or greater);
- For Arm A only: Any other major medical illness that, in the investigator's opinion, would: (1) prevent administration or completion of institution's standard of care FOLFOX/bevacizumab therapy; (2) prevent administration or completion of protocol-specified imaging; and/or (3) interfere with follow-up.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Colorectal Cancer, Hepatic Metastasis
Eligible participants in Arm A enrolled in this imaging study will: be older than 18, have metastatic colorectal cancer with at least one hepatic lesion, and be treated with FOLFOX in combination with bevacizumab.
|
Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy.
Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
Other Names:
|
Primary Tumor Undefined, Hepatic Metastasis
Eligible participants in Arm B enrolled in this imaging study will: be older than 18, must have prior histological documentation of any types of cancer with metastasis to the liver, and must be in stable treatment conditions prior to and between scans.
|
Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy.
Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the reproducibility of DCE-MRI measures of tumor Ktrans, kep, and ve for colorectal metastases to the liver (Arm A) and any cancer metastatic to the liver (Arm B), using projection interleaved back-projection DCE-MRI techniques.
Time Frame: Three (3) DCE-MRI scans (two separate pre-treatment and one post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab])
|
Three (3) DCE-MRI scans (two separate pre-treatment and one post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab])
|
To determine the alteration in tumor vascularity (assessed by percentage change in tumor Ktrans) in Arm A participants with metastatic colorectal cancer to the liver after one cycle of chemotherapy including bevacizumab compared to baseline Ktrans value.
Time Frame: Two (2) DCE-MRI scans (baseline pre-treatment and post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab])
|
Two (2) DCE-MRI scans (baseline pre-treatment and post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab])
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the relationship between initial tumor vascularity (absolute tumor Ktrans) and change in tumor vascularity (percentage change in tumor Ktrans after one cycle of chemotherapy) and PFS in participants in Arm A.
Time Frame: Two (2) DCE-MRI scans (baseline pre-treatment and post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab]) with follow-up
|
Two (2) DCE-MRI scans (baseline pre-treatment and post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab]) with follow-up
|
To evaluate the perfusional difference between the dominant tumor and the global tumor burden (Arms A and B).
Time Frame: Three (3) DCE-MRI scans (two separate pre-treatment and one post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab])
|
Three (3) DCE-MRI scans (two separate pre-treatment and one post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab])
|
To evaluate the feasibility of exporting back-projection DCE-MRI imaging across multiple MRI scanner vendor platforms for use in a multi-site chemotherapy trial.
Time Frame: Three (3) DCE-MRI scans (two separate pre-treatment and one post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab])
|
Three (3) DCE-MRI scans (two separate pre-treatment and one post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab])
|
To determine the functional status as a predictor of response or disease-free survival in participants in Arm A.
Time Frame: Three (3) DCE-MRI scans (two separate pre-treatment and one post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab]) with follow-up for response and disease-free survival
|
Three (3) DCE-MRI scans (two separate pre-treatment and one post-treatment DCE-MRI exams [post-treatment defined as after the first cycle of chemotherapy with bevacizumab]) with follow-up for response and disease-free survival
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark Rosen, MD, PhD, University of Pennsylvania
- Study Chair: Larry Dougherty, PhD, University of Pennsylvania
- Study Chair: Donald Mitchell, MD, Thomas Jefferson University
- Study Chair: Peter J O'Dwyer, MD, University of Pennsylvania
- Study Chair: Michael D Feldman, MD, PhD, University of Pennsylvania
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACRIN PA 4002
- SAP #4100031303
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Neoplasm
-
Azienda Ospedaliera di PadovaIstituto Oncologico Veneto IRCCSRecruitingColorectal Adenocarcinoma | Colorectal Liver Metastases | Unresectable Malignant NeoplasmItaly
-
Carol Davila University of Medicine and PharmacyRecruitingNeoplasm, Colorectal | Neoplasm, Stomach | Neoplasm, Esophagus | Neoplasm, DuodenalRomania
-
Koen RoversHoffmann-La Roche; Comprehensive Cancer Centre The Netherlands; Dutch Cancer...RecruitingColorectal Cancer | Peritoneal Neoplasms | Colorectal Neoplasm | Peritoneal Carcinomatosis | Colorectal Carcinoma | Peritoneal Cancer | Peritoneal Metastases | Colorectal Adenocarcinoma | Colorectal Neoplasms Malignant | Peritoneal Neoplasm Malignant Secondary Carcinomatosis | Peritoneal Neoplasm Malignant...Netherlands, Belgium
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMetastatic Malignant Neoplasm in the Liver | Advanced Malignant Neoplasm | Refractory Malignant Neoplasm | Colorectal Carcinoma Metastatic in the LiverUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityUnknownColorectal Cancer | Neoplasm | Metastatic NeoplasmChina
-
Mayo ClinicRecruitingColorectal Cancer | Colorectal Liver MetastasesUnited States
-
Fundació Institut de Recerca de l'Hospital de la...UnknownColorectal Cancer | AngiogenesisSpain
-
TransgeneTerminatedColorectal Neoplasm | Digestive System NeoplasmFrance, Spain, Belgium
-
Bristol-Myers SquibbNovartisActive, not recruitingColorectal Cancer | Colorectal Neoplasm | Colorectal Tumors | Colorectal CarcinomaItaly, United States, Canada, Spain, Argentina, Australia, Belgium, Chile, Czechia, Germany
Clinical Trials on DCE-MRI
-
Stanford UniversityColumbia University; University of ManchesterRecruiting
-
Yonsei UniversityUnknownAdvanced Adult Hepatocellular CarcinomaKorea, Republic of
-
American College of Radiology Imaging NetworkNational Cancer Institute (NCI); Eastern Cooperative Oncology GroupUnknownBreast Cancer | BIRADS 3 | BIRADS 4 | BIRADS 5United States
-
University of UtahCompleted
-
Memorial Sloan Kettering Cancer CenterUniversity of Oregon; University College, London; New York Presbyterian Hospital and other collaboratorsCompleted
-
OHSU Knight Cancer InstituteRadiological Society of North America; Medical Research Foundation, OregonTerminatedHead and Neck CancerUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedOvarian CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institute of Dental and Craniofacial...Recruiting
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)Active, not recruitingHead and Neck CancerUnited States
-
Dartmouth-Hitchcock Medical CenterUniversity of Maryland, Baltimore; National Institute of Arthritis and Musculoskeletal... and other collaboratorsRecruiting